Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed unresectable, advanced, and/or metastatic disease meeting one of the following types:
• * Gastroentero-neuroendocrine tumor of the foregut
• * Pancreatic neuroendocrine tumor
• * Neuroendocrine tumor of unknown primary
• Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (the longest diameter) ≥ 20 mm by conventional CT scanning or ≥ 10 mm by spiral CT scan or MRI
• No bronchial neuroendocrine tumors (NETs) or other NETs where the primary site is situated in organs above the diaphragm (e.g., laryngeal and pharyngeal NETs)
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-2
• Life expectancy ≥ 12 weeks
• Hemoglobin ≥ 10 g/dL
• Platelet count ≥ 100,000/mm³
• WBC ≥ 3,000/mm³
• ANC ≥ 1,500/mm³
• Bilirubin ≤ 2 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 5 times ULN
• AST and ALT ≤ 5 times ULN
• GFR ≥ 60 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 3 months after completion of study therapy
• No other serious or uncontrolled illness that would preclude study participation
• No medical or psychiatric condition that would influence the ability to provide consent
• PRIOR CONCURRENT THERAPY:
• At least 3 weeks since prior interferon therapy
• No prior systemic chemotherapy or chemotherapy administered as part of a chemo-embolization regimen, or for this condition
• No receptor-targeted radiolabeled therapy within the past 6 months
• No investigational agent within the past 4 weeks
• Prior and concurrent somatostatin analogues allowed provided symptoms are no longer controlled by this treatment or there is documented measurable disease progression on serial CT scans performed up to 6 months apart
• No palliative radiotherapy involving lesions used to measure disease
• * Palliative radiotherapy to regions not involved in measurement of disease allowed
• No other concurrent chemotherapy for this condition